top of page
Search

MarketAxess (MKTX)

  • Writer: Abacus Research
    Abacus Research
  • Feb 3, 2023
  • 1 min read

We see an opportunity to own a great long term asset that can compound 10%+. We like everything about MKTX, the high quality, low capital intensity, depressed margins, the recent stock weakness, plus the highly likely cyclical rebound.

  • The market is worried on two fronts:

    1. Tradeweb taking share

    2. Fee compression which is driven by cyclical factors-

  • We think both concerns are overdone. Our 2024 EBITDA estimates are 20% above consensus.

  • The challenge has always been valuation, how much should we pay for this sort of asset? After the derating, we think it is easier than it has been.

Potential Upside: $410-$430 (+27%) Sensible Downside: $275 (-18%)


 
 
 

Recent Posts

See All
Axon:

Axon is shifting from selling individual tools to providing an interconnected ecosystem. Hardware like TASERs and cameras now act as "data generators" that feed directly into high-margin software modu

 
 
 
C.H. Robinson

CHRW has been going through significant change, They are retaking market share. The new CEO has transformed the company by bringing in a lean / AI, that has helped CHRW to grow earnings despite strugg

 
 
 
Brookfield (BN):

We initially wrote up BN in Jan 2024, it has increased 70%, so why mention it again? Firstly, we think the fundamentals are as good now as they were 2 yrs ago, with a >15% IRR on offer. BN is not a we

 
 
 

Comments

bottom of page